Amgen (BUE:AMGN) Margin of Safety % (DCF FCF Based) : 95.75% (As of Apr. 27, 2024)

View and export this data going back to . Start your Free Trial

What is Amgen Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

As of today (2024-04-27), Amgen's Predictability Rank is 4-Stars. Amgen's intrinsic value calculated from the Discounted FCF model is ARS405975.66 and current share price is ARS9775.00. Consequently,

Amgen's Margin of Safety % (DCF FCF Based) using Discounted FCF model is 95.75%.

Competitive Comparison of Amgen's Margin of Safety % (DCF FCF Based)

For the Drug Manufacturers - General subindustry, Amgen's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Amgen's Margin of Safety % (DCF FCF Based) Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Amgen's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where Amgen's Margin of Safety % (DCF FCF Based) falls into.

Amgen Margin of Safety % (DCF FCF Based) Calculation

Amgen's Margin of Safety % (DCF FCF Based) for today is calculated as

Margin of Safety % (DCF FCF Based)	=	(Intrinsic Value: DCF (FCF Based)	-	Current Price)	/	Intrinsic Value: DCF (FCF Based)
	=	(229912.13	-	9775.00)	/	229912.13
	=	95.75 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The intrinsic value is calculated from the Discounted FCF model with default parameters. The calculation method is the same as Discounted Earnings model except free cash flow are used in the calculation instead of earnings per share.

Amgen Margin of Safety % (DCF FCF Based) Related Terms

Thank you for viewing the detailed overview of Amgen's Margin of Safety % (DCF FCF Based) provided by GuruFocus.com. Please click on the following links to see related term pages.

Amgen (BUE:AMGN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amgen Inc (BUE:AMGN) » Definitions » Margin of Safety % (DCF FCF Based)

Comparable Companies

Traded in Other Exchanges

AMGN:USA AMG N:Mexico AMGd:UK 0R0T:UK AMG:Germany AMGN34:Brazil AMGN:Austria

Address

One Amgen Center Drive, Thousand Oaks, CA, USA, 91320-1799

Website

https://www.amgen.com

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.